SUBSCRIBE
Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2009, Vol. 7 ›› Issue (11): 1023-1034.doi: 10.3736/jcim20091102

• Systematic Review • Previous Articles     Next Articles

Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: A systematic review and meta-analysis

Shuang-nian Xua,Jie-ping Chena,Jian-ping Liub,Yun Xiab   

  1. a Center for Hematology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
    b Center for Evidence-Based Medicine,Beijing University of Chinese Medicine, Beijing 100029, China
  • Received:2009-06-04 Accepted:2009-08-13 Online:2009-11-20 Published:2009-11-15
  • Contact: Jie-ping Chen,Jian-ping Liu E-mail:chenjpxn@yahoo.com.cn;jianping_l@hotmail.com

RichHTML

4

PDF (PC)

60

Like

Background

The studies have demonstrated that arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) takes effects in treatment of acute promyelocytic leukemia (APL) through different underlying mechanisms. This has established the molecular foundation of ATO plus ATRA therapy. Currently, ATO plus ATRA has also been widely used in clinical practice.
Objective

To assess the efficacy and safety of ATO in combination with ATRA for APL.
Search strategy

The Cochrane Library (Issue 1, 2009), Cochrane Central Register of Controlled Trials (from 1970 to January 2009), MEDLINE (from 1978 to October 2008), EMBASE (from 1950 to March 2009), Chinese Biological Medical Literature Database (from 1978 to December 2008), CNKI (from 1994 to December 2008), China Medical Academic Conference Database (from 1994 to December 2008) were electronically searched. We also searched the Meta-Register of Controlled Trials, Conference Proceedings of American Society of Hematology (from 1946 to December 2008) and Conference Proceedings of American Society of Clinical Oncology (from 1946 to December 2008) on the internet for grey literature. The authors also hand-searched Chinese periodicals potentially related to the question including Chinese Journal of Hematology, Journal of Experimental Hematology and Journal of Clinical Hematology.
Inclusion criteria

All randomized controlled trials comparing ATO plus ATRA with other regimens for the treatment of APL were included. Intervention and comparison regimens include: 1) ATO plus ATRA vs ATO monotherapy; 2) ATO plus ATRA vs ATRA monotherapy; 3) ATO plus ATRA vs ATRA plus chemotherapy; 4) ATO plus ATRA vs ATO+ATRA+chemotherapy.
Data extraction and analysis

Related data concerning complete remission rate, overall survival rate, and disease free survival rate, time to complete remission, relapse rate, mortality and adverse reactions were extracted independently by two reviewers. The different statistical methods were applied according to different data type with RevMan 5.0 software.
Results

After merging of the included trials, seven eligible randomized controlled trials with 392 cases were analyzed, among which 6 RCTs were methodologically graded as middle and one as of high risk of bias. The control therapies included ATO monotherapy, ATRA monotherapy and chemotherapy with ATO plus ATRA. Compared with ATO monotherapy, ATO plus ATRA could improve time to complete remission and relapse rate of newly diagnosed APL, but could not improve the complete remission rate, disease free survival rate, mortality and liver dysfunction of relapsed APL patients based on meta-analysis and sensitivity analysis. Compared with ATRA monotherapy, ATO plus ATRA shortened the time to complete remission, improved the disease free survival rate and relapse rate, but increased the incidence of edema during the treatment. Compared with chemotherapy with ATO plus ATRA, ATO plus ATRA could improve the complete remission rate, relapse rate, mortality and adverse reactions.
Conclusion

For newly diagnosed APL, ATO plus ATRA is superior to ATO monotherapy, ATRA monotherapy and chemotherapy with ATO plus ATRA, but due to the lack of data about comparison with the current standard treatment regimen (ATRA plus chemotherapy), it is not enough to recommend ATO plus ATRA as a frontline therapy. For relapsed APL, ATO plus ATRA is not superior to ATO monotherapy, and ATRA plus ATO is not a supportive therapy. Due to limitation of sample size and risk of bias from the included trials, the effects of ATO plus ATRA need to be confirmed by large and high-quality randomized controlled trials.

Key words: Arsenic trioxide, Leukemia, Promyelocytic, Acute, Randomized controlled trial, Systematic review, Meta-analysis

Figure 1

Flow diagram of literature searching and screening"

Table 1

Basic characteristics of the included studies"

Basic characteristics Dombret et al[14] Raffoux et al[15] Ren et al[16] Yang et al[17]
ATO plus ATRA ATO ATO plus ATRA ATO ATO plus ATRA ATO ATO plus ATRA ATO
Cases NA NA 10 10 43 52 15 11
Male/Female 6/4 6/4 6/4 23/20 30/22 5/10 4/7
Median age (years) 47 NA NA 34 32 39 41
Mean white blood cell count
($\bar{x}$±s , ×109/L)		 NA NA NA NA 13.6±23.9 11.9±21.5 NA NA
Disease condition Relapsed Relapsed Newly diagnosed Newly diagnosed
Basic characteristics Shen et al[18] Su et al[19] Zhong et al[20,21,22]
ATO plus ATRA ATO ATRA ATO plus
ATRA		 ATO ATRA ATO plus
ATRA		 ATO
Cases 21 20 20 40 30 36 38 36
Male/Female 12/9 12/8 9/11 19/21 12/18 18/18 23/15 22/14
Median age (years) 34 39 30.5 37.2 31 33.3 23 22
Mean white blood cell count
($\bar{x}$±s×109/L)		 NA NA NA 15.7±20.6 13.6±23.9 11.9±21.5 26.3±19.2 27.4±18.3
Disease condition Newly diagnosed Newly diagnosed Newly diagnosed

Table 2

Intervention regimens of the included studies"

Study ATO ATRA ATO plus ATRA ATO, ATRA, and
chemotherapy
Dombret et al[14] 0.15 mg/（kg·d） NA ATO 0.15 mg/(kg·d)+
ATRA 45 mg/(m2·d)		 NA
Raffoux et al[15] 0.15 mg/(kg·d) NA ATO 0.15 mg/(kg·d)+
ATRA 45 mg/(m2·d)		 NA
Ren et al[16] NA 25 mg/(m2·d) ATO 10 mg/d+
ATRA 25 mg/(m2·d)		 NA
Yang et al[17] NA 30-60 mg/d ATO 10 mg/d+
ATRA 30-60 mg/d		 NA
Su et al[18] 0.16 mg/(kg·d) 25 mg/(m2·d) ATO 0.16 mg/(kg·d)+
ATRA 30-40 mg/d		 NA
Shen et al[19] 0.16 mg/(kg·d) 25 mg/(m2·d) ATO 0.16 mg/(kg·d)+
ATRA 25 mg/(m2·d)		 NA
Zhong et al [20,21,22] NA NA ATO 10 mg/d+
ATRA 45 mg/(m2·d)		 ATO 10 mg/d+ATRA 45 mg/(m2·d)+DA/MA

Figure 2

Risk of bias from the included trials"

Figure 3

Summary of the risk of bias from the included trials"

Figure 4

Meta-analysis of relapse rate between ATO plus ATRA and ATO monotherapy"

Figure 5

Meta-analysis of relapse rate between ATO plus ATRA and ATRA monotherapy"

Figure 6

Meta-analysis of incidence of edema between ATO plus ATRA and ATO monotherapy"

Table 3

Sensitivity analysis of different outcomes between ATO plus ATRA and ATO monotherapy according to disease conditions"

Outcome Newly diagnosed APL patients
(result of sensitivity analysis and 95% CI)		 Relapsed APL patients
(result of sensitivity analysis and 95% CI)
Complete remission rate 1.67 [0.61, 4.59] 1.18 [0.20, 7.08]
Disease free survival rate 0.12 [0.01, 1.83] 2.36 [0.55, 10.07]
Mortality 0.64 [0.21, 1.93] 1.33 [0.21, 8.35]
Liver dysfunction 1.33 [0.38, 4.62] 1.00 [0.17, 5.98]
[1] Lu DP. Therapeutics of leukemia[M]. Beijing: Science Press, 1992: 152
陆道培 . 白血病治疗学[M]. 北京: 科学出版社, 1992: 152
[2] Mistry AR, Pedersen EW, Solomon E, Grimwade D . The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease[J]. Blood Rev, 2003,17(2):71-97
doi: 10.1016/S0268-960X(02)00075-9
[3] Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L . A randomized comparison of all transretinoic acid(ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia[J]. The European APL Group Blood, 1999,94(4):1192-1200
Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C , Degos L.A randomized comparison of all transretinoic acid(ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia.[J]. The European APL Group Blood, 1999,94(4):1192-1200
[4] Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM , Wiernik PH.All-trans-retinoic acid in acute promyelocytic leukemia[J]. N Engl J Med, 1997,337(15):1021-1028
doi: 10.1056/NEJM199710093371501
[5] Wang ZY , Chen Z.A cute promyelocytic leukemia: from highly fatal to highly curable[J]. Blood, 2008,111(5):2505-2515
doi: 10.1182/blood-2007-07-102798 pmid: 18299451
[6] Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A , Jakubowski A.Differentiation therapy of acute promyelocytic leukemia with tretinoin(all-trans-retinoic acid[J]. N Engl J Med, 1991,324(20):1385-1393
doi: 10.1056/NEJM199105163242002
[7] Douer D , Tallman MS.Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies[J]. J Clin Oncol, 2005,23(10):2396-2410
doi: 10.1200/JCO.2005.10.217 pmid: 15800332
[8] Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S , Wang ZY, de Thé H, Chen SJ, Chen Z. Use of arsenic trioxide(As2O3) in the treatment of acute promyelocytic leukemia(APL): Ⅰ. As2O3 exerts dose-dependent dual effects on APL cells[J]. Blood, 1997,89(9):3345-3353
doi: 10.1007/BF02781736 pmid: 10703942
[9] Davison K, Mann KK , Miller WH.Arsenic trioxide: mechanisms of action[J]. Semin hematol, 2002,39(2 Suppl 1):3-7
doi: 10.1016/S0037-1963(02)70011-5
[10] Zheng PZ, Wang KK, Zhang QY, Huang QH, Du YZ, Zhang QH, Xiao DK, Shen SH, Imbeaud S, Eveno E, Zhao CJ, Chen YL, Fan HY, Waxman S, Auffray C, Jin G, Chen SJ, Chen Z, Zhang J . Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia[J]. Proc Natl Acad Sci U S A, 2005,102(21):7653-7658
doi: 10.1073/pnas.0502825102
[11] Zhou GB, Zhang J, Wang ZY, Chen SJ , Chen ZT.reatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy[J]. Philos Trans R Soc Lond B Biol Sci, 2007,362(1482):959-971
doi: 10.1098/rstb.2007.2026
[12] Higgins J, Green S . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. Oxford: The Cochrane Library. 2008.
[13] Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR . Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials, 2007,8:16
doi: 10.1186/1745-6215-8-16 pmid: 1920534
Tierney JF, Stewart LA, Ghersi D, Burdett S , Sydes MR.Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials, 2007,8:16
[14] Dombret H, Rousselot P, Hermine O, Fermand JP, Poupon J, Daniel MT, Chomienne C, Tibbi A, Lebbe G, Solbes LS, Brouet JC, Varet B , Degos L.Treatment of relapsing acute promyelocytic leukemia(APL) with arsenic trioxide(As2O3) all-trans retinoic acid(ATRA): the French As98 study[J]. Blood, 2000,96(11):828a
[15] Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C , Fermand JP, de Thé H, Degos L, Hermine O, Dombret H. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia[J]. J Clin Oncol, 2003,21(12):2326-2334
doi: 10.1200/JCO.2003.01.149
[16] Ren JH, Lin FR, Guo XN, Wang Y, Zhang JN, Wang Y , Dong ZR.Clinical observation on treatment of acute promyelocytic leukemia with all-trans retinoic acid, arsenic trioxide and chemotherapy[J]. Zhonghua Xue Ye Xue Za Zhi, 2004,25(7):437-438
doi: 10.3760/j:issn:0253-2727.2004.07.016
任金海, 林凤茹, 郭晓楠, 王颖, 张静楠, 王艳 , 董作仁全反式维甲酸、三氧化二砷及联合化疗治疗急性早幼粒细胞白血病临床观察[J]. 中华血液学杂志, 2004,25(7):437-438
doi: 10.3760/j:issn:0253-2727.2004.07.016
[17] Yang EQ, Liu ZM, He C . Efficacy of all-trans retinoic acid and arsenic trioxide in treatment of newly diagnosed acute promyelocytic leukemia[J]. Bai Xue Bing Lin Ba Liu, 2006,15(3):216-217
杨恩芹, 刘志梅, 贺春 . 维A酸与亚砷酸联合治疗初发的急性早幼粒细胞白血病疗效分析[J]. 白血病·淋巴瘤, 2006,15(3):216-217
[18] Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang ZY, Chen SJ , Chen Z . All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.[J]. Proc Natl Acad Sci U S A. ;, 2004,101((15):5328-5335
doi: 10.1073/pnas.0400053101
[19] Su XL, Xia WL . Clinical observation of all-trans retinoic acid and arsenic trioxide in treatment of newly diagnosed acute promyelocytic leukemia[J]. Ji Ceng Yi Xue Lun Tan, 2006,10(4):338-339
doi: 10.3969/j.issn.1672-1721.2006.07.030
苏秀连, 夏维林 . 维甲酸联合砷剂治疗初发APL的临床疗效观察[J]. 基层医学论坛, 2006,10(4):338-339
doi: 10.3969/j.issn.1672-1721.2006.07.030
[20] 钟灼, 刘珍才, 李建炜, 蔡卓夫, 邓春晓, 刘鹏, 观美华, 黄妙儿, 郭晓华, 王飞, 马永华, 钟彩玲, 殷文龙, 高利霞, 蔡玉桂 . 亚砷酸联合维甲酸治疗急性早幼粒细胞白血病6年临床观察[J]. 临床血液学杂志, 2008,3:244-246
doi: 10.3969/j.issn.1004-2806.2008.03.006
Zhong Z, Liu ZC, Li JW, Cai ZF, Deng CX, Liu P, Guan MH, Huang ME, Guo XH, Wang F, Ma YH, Zhong CL, Yin WL, Gao LX, Cai YG . The clinical observation on arsenic trioxide associated with ATRA in treating acute promyelocytic leukemia for six years[J]. Lin Chuang Xue Ye Xue Za Zhi, 2008,3:244-246
[21] Deng CX, Liang GZ , Deng CY .Pure arsenic trioxide in combination with all-trans retinoic acid treatment of acute promyelocytic leukemia[J]. Qiqihaer Yi Xue Yuan Xue Bao, 2007,28(12):1411-1412
邓春晓, 梁桂珍 , 邓才英单纯亚砷酸联合维甲酸治疗急性早幼粒细胞白血病不良反应6年观察及对策.[J]. 齐齐哈尔医学院学报, 2007,28(12):1411-1412
[22] Zhong Z, Liu ZC , Li JW .The clinical observation on arsenic trioxide with ATRA in treating acute promyelocytic leukemia for six years[J]. Blood, 2007,110(11):2868a
[23] National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology [2008-09-20]. .
[1] Chiung-Hui Huang, Mei-Ling Yeh, Fang-Pey Chen, Daphne Wu. Low-level laser acupuncture reduces postoperative pain and morphine consumption in older patients with total knee arthroplasty: A randomized placebo-controlled trial. Journal of Integrative Medicine, 2022, 20(4): 321-328.
[2] Ming-min Xu, Pei Guo, Qing-yu Ma, Xuan Zhou, Yu-long Wei, Lu Wang, Yue Chen, Yu Guo. Can acupuncture enhance therapeutic effectiveness of antidepressants and reduce adverse drug reactions in patients with depression? A systematic review and meta-analysis. Journal of Integrative Medicine, 2022, 20(4): 305-320.
[3] Jia-yi Zhao, Jin Pu, Jian Fan, Xin-yu Feng, Jian-wen Xu, Rong Zhang, Yan Shang. Tanshinone IIA prevents acute lung injury by regulating macrophage polarization. Journal of Integrative Medicine, 2022, 20(3): 274-280.
[4] Ting-ting Lu, Cun-cun Lu, Mei-xuan Li, Li-xin Ke, Hui Cai, Ke-hu Yang. Reporting and methodological quality of meta-analyses of acupuncture for patients with migraine: A methodological investigation with evidence map. Journal of Integrative Medicine, 2022, 20(3): 213-220.
[5] Maryam Azimi, Hanieh Niayesh, Mahboobeh Raeiszadeh, Sedigheh Khodabandeh-shahraki. Efficacy of the herbal formula of Foeniculum vulgare and Rosa damascena on elderly patients with functional constipation: A double-blind randomized controlled tria. Journal of Integrative Medicine, 2022, 20(3): 230-236.
[6] Ubiratan Cardinalli Adler, Maristela Schiabel Adler, Ana Elisa Madureira Padula, Livia Mitchiguian Hotta, Amarilysde Toledo Cesar, José Nelson Martins Diniz, Helen de Freitas Santos, Edson Zangiacomi Martinez. Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-Simile study). Journal of Integrative Medicine, 2022, 20(3): 221-229.
[7] Xin Wang, Wen-juan Song, Yi Ruan, Bing-chu Li, Can Lü, Nian Huang, Fan-fu Fang, Wei Gu. Core muscle functional strength training for reducing the risk of low-back pain in military recruits: An open-label randomized controlled trial. Journal of Integrative Medicine, 2022, 20(2): 145-152.
[8] Witoo Dilokthornsakul, Ramanya Kosiyaporn, Rattanamanee Wuttipongwaragon, Piyameth Dilokthornsakul. Potential effects of propolis and honey in COVID-19 prevention and treatment: A systematic review of in silico and clinical studies. Journal of Integrative Medicine, 2022, 20(2): 114-125.
[9] Deng-chao Wang, Miao Yu, Wen-xian Xie, Li-yan Huang, Jian Wei, Yue-hua Lei. Meta-analysis on the effect of combining Lianhua Qingwen with Western medicine to treat coronavirus disease 2019. Journal of Integrative Medicine, 2022, 20(1): 26-33.
[10] Jun-peng Yao, Li-ping Chen, Xian-jun Xiao, Ting-hui Hou, Si-yuan Zhou, Ming-min Xu, Kai Wang, Yu-jun Hou, Lin Zhang, Ying Li. Effectiveness and safety of acupuncture for treating functional constipation: An overview of systematic reviews. Journal of Integrative Medicine, 2022, 20(1): 13-25.
[11] Yang-hao-tian Wu, Wen-bo He, Yin-yan Gao, Xue-mei Han. Effects of traditional Chinese exercises and general aerobic exercises on older adults with sleep disorders: A systematic review and meta-analysis. Journal of Integrative Medicine, 2021, 19(6): 493-502.
[12] Yi Yuan, Rui-Ting Wang, Jun Xia, Hui-Juan Cao. Interventions for preventing influenza: an overview of Cochrane systematic reviews and a Bayesian network meta-analysis. Journal of Integrative Medicine, 2021, 19(6): 503-514.
[13] Meng-zhu Zhao, Chen Zhao, Shuang-shuang Tu, Xu-xu Wei, Hong-cai Shang. Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials. Journal of Integrative Medicine, 2021, 19(4): 317-326.
[14] Si-chun Gu, Jie Zhou, Qing Ye, Can-xing Yuan. Pingchan granule for depressive symptoms in Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Journal of Integrative Medicine, 2021, 19(2): 120-128.
[15] Jie Wu, Shu-wei Duan, Hong-tao Yang, Yue-yi Deng, Wei Li, Ya-ni He, Zhao-hui Ni, Yong-li Zhan, Shan Lin, Zhi-yong Guo, Jun Zhu, Jing-ai Fang, Xu-sheng Liu, Li-hua Wang, Rong Wang, Nian-song Wang, Xiao-hong Cheng, Li-qun He, Ping Luo, Shi-ren Sun s, Ji-feng Sun, Ai-ping Yin, Geng-ru Jiang, Hong-yu Chen, Wen-hu Liu, Hong-li Lin, Meng Liang, Lu Ma, Ming Chen, Li-qun Song, Jian Chen, Qing Zhu, Chang-ying Xing, Yun Li, Ji-ning Gao, Rong-shan Li, Ying Li, Hao Zhang, Ying Lu, Qiao-ling Zhou, Jun-zhou Fu, Qiang He, Guang-yan Cai, Xiang-mei Chen. Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial. Journal of Integrative Medicine, 2021, 19(2): 111-119.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Wei-xiong Liang. Problems-solving strategies in clinical treatment guideline for traditional Chinese medicine and integrative medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 1-4
[2] Zhao-guo Li. Discussion on English translation of commonly used sentences in traditional Chinese medicine: part one. Journal of Chinese Integrative Medicine, 2008, 6(1): 107-110
[3] Jun Hu, Jian-ping Liu. Non-invasive physical treatments for chronic/recurrent headache. Journal of Chinese Integrative Medicine, 2008, 6(1): 31
[4] Xue-mei Liu, Qi-fu Huang, Yun-ling Zhang, Jin-li Lou, Hong-sheng Liu, Hong Zheng. Effects of Tribulus terrestris L. saponion on apoptosis of cortical neurons induced by hypoxia-reoxygenation in rats. Journal of Chinese Integrative Medicine, 2008, 6(1): 45-50
[5] . Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication (Chinese version, part two). Journal of Chinese Integrative Medicine, 2010, 8(11): 1001-1005
[6] Daniel Weber, Janelle M Wheat, Geoffrey M Currie. Inflammation and cancer: Tumor initiation, progression and metastasis,and Chinese botanical medicines. Journal of Chinese Integrative Medicine, 2010, 8(11): 1006-1013
[7] Hong Liu , Guo-liang Zhang, Li Shen , Zhen Zeng, Bao-luo Zhou, Cheng-hai Liu, Guang Nie . Application and evaluation of a pseudotyped virus assay for screening herbs for anti-H5Nl avian influenza virus. Journal of Chinese Integrative Medicine, 2010, 8(11): 1036-1040
[8] Zhao-guo Li . A discussion of English translation of 1995 and 1997 Chinese National Standards of Traditional Chinese Medical Terminologies for Clinical Diagnosis and Treatment. Journal of Chinese Integrative Medicine, 2010, 8(11): 1090-1096
[9] Rui Jin, Bing Zhang. A complexity analysis of Chinese herbal property theory: the multiple formations of herbal property (Part 1). Journal of Chinese Integrative Medicine, 2012, 10(11): 1198-1205
[10] Hui-min Liu, Xian-bo Wang, Yu-juan Chang, Li-li Gu. Systematic review and meta-analysis of randomized controlled trials of integrative medicine therapy for treatment of chronic severe hepatitis. Journal of Chinese Integrative Medicine, 2012, 10(11): 1211-1228
Journal of Integrative Medicine, ISSN: 2095-4964 CN 31-2083/R
Copyright © Journal of Integrative Medicine
Powered by Beijing Magtech Co. Ltd
沪公网安备31010602003416号      沪ICP备18017633号-3